Clinical Trials Logo

Clinical Trial Summary

During surgery in which the thyroid is removed (thyroidectomy), the identification of parathyroid glands, that should be saved, can be challenging. Therefore, there is need for accurate intraoperative guidance. Earlier animal studies show that the parathyroid glands can be identified by the use of the Near Infrared Fluorescent dye Indocyanine green (ICG).

Our hypothesis is therefore, that the use of ICG-based fluorescence imaging during thyroid surgery will provide real-time intraoperative visualization of the parathyroid glands.

This prospective observational feasibility study aims to evaluate the feasibility of the use of ICG in identifying the parathyroid glands during thyroid surgery. 30 patients (age >18 years) who are already regularly scheduled for thyroid surgery; i.e. patients undergoing total thyroidectomy are suitable for inclusion. In all patients, undergoing total thyroidectomy infrared fluorescence imaging, using a per-operative intravenous injection of 7.5 mg ICG, will be tested on feasibility and imaging characteristics.


Clinical Trial Description

In this study, the feasibility of the use of NIR fluorescence imaging for the identification of the parathyroid glands during thyroid surgery will be explored.

Per-operatively: The surgery will start as usual. When the surgeon would normally search for the parathyroid glands, 7.5 mg of ICG will be administered intravenously through the infusion in the patients arm. An intravenous administration is chosen because of the minimal invasive nature and results of the described earlier case series in which ICG was also administered via peripheral infusion. Directly after that, the fluorescence system can be switched to fluorescence mode. The surgeon will determine whether the parathyroid glands are visible now. If needed, due to washout, a second dose of 7.5 mg of ICG can be administered. After identification of the parathyroid glands, surgery will continue as in the standard situation, until there is a desire to visualize the parathyroid glands again, then another dose of ICG can be given. Time until first identification of the parathyroid glands and total surgical time will be measured. After complete removal of the thyroid, another 7.5 mg of ICG will be administered intravenously to visualize the vascularization of the parathyroid gland. The intensity will be subjectively scored: 1 parathyroid black after injection of ICG, 2 partially vascularized, or 3 parathyroid is green; well vascularized. The fluorescence system will be used to record the whole procedure. Directly after the procedure the researcher will ask the surgeon whether he or she thinks the technique is feasible.

Postoperatively: As in standard care, after thyroid surgery, the serum calcium levels will be determined. Low calcium levels can indicate misidentification of parathyroid glands. These calcium levels are determined only in patients after total thyroidectomy on day 1, 2 and after two weeks. Also TSH will be determined after two weeks as in standard care. The thyroid specimen will be send to pathology. In the specimen, the pathologist will search for parathyroid glands, as is standard care. Furthermore, video recordings will be analyzed, quantifying the fluorescence signal compared to the background: measuring the Target to Background Ratio. Also, in these video recordings the time until visualization of the parathyroid glands will be reassessed by an independent expert. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03012438
Study type Interventional
Source Maastricht University Medical Center
Contact
Status Completed
Phase N/A
Start date March 23, 2017
Completion date March 12, 2018

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05836246 - The Development of Quantitative Ultrasound Imaging Software Platform
Active, not recruiting NCT05579782 - Assessing Benefits of NIRAF Detection for Identifying Parathyroid Glands During Total Thyroidectomy N/A
Completed NCT04124705 - A Study of Armour® Thyroid Compared to Synthetic T4 (Levothyroxine) in Previously Hypothyroid Participants Phase 2
Enrolling by invitation NCT06028282 - Post-RAI Therapy Dosimetry and Quality Assessment of Target Tissue Dosing
Recruiting NCT05626010 - Efficacy of Acetaminophen-ibuprofen Combination on the Postoperative Pain After Thyroidectomy N/A
Completed NCT01805856 - Antimicrobial Prophylaxis in Thyroid and Parathyroid Surgery N/A
Completed NCT03640247 - Pain Medications Following Thyroidectomy and Parathyroidectomy Phase 1
Recruiting NCT05117853 - Autofluorescence and Indocyanine Green to Avoid Hypocalcemia After Thyroidectomy Phase 3
Completed NCT00592605 - Thyroid Disease Serum Repository N/A
Completed NCT04344886 - Optimization and Individualization of Diagnostic Scintigraphy Protocol and Minimally Invasive Radio-guided Parathyroid Surgery N/A
Completed NCT00846755 - Thyroid Disease in Pregnancy: Case Finding Versus Universal Screening N/A
Completed NCT04635813 - The Impact of COVID-19 Pandemic on Thyroid Surgery in Italy: Results From a Nation-wide Multicentric Study
Not yet recruiting NCT05432050 - Bispectral Index and Patient State Index During General Anesthesia With Remimazolam
Recruiting NCT03191188 - A Pilot Feasibility Trial of Thyroid Hormone Replacement in Dialysis Patients N/A
Recruiting NCT06296420 - Dysphagia After Thyroidectomy
Completed NCT02981095 - Effect of Bupivacaine Application on Postthyroidectomy Pain N/A
Completed NCT01539499 - Complications of Endocrine Surgery: Data From the United HealthSystem Consortium N/A
Completed NCT05421559 - Transection of Sternothyroid Muscle Increases the Rate of Exposure of the External Laryngeal Nerve During Thyroidectomy N/A
Completed NCT00054756 - Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities Phase 2
Completed NCT02951000 - Platysma Trial - Platysma Suturing Versus no Sutures for Wound Closure After Primary Thyroid Surgery N/A